Relationships between serum biomarker levels and clinical presentation of human osteosarcomas

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 7, 2011, Pages 1717-1722

  Limmahakhun, Sakkadech ^a   Pothacharoen, Peraphan ^a   Theera Umpon, Nipon ^b   Arpornchayanon, Olarn ^a   Leerapun, Taninnit ^a   Luevitoonvechkij, Sirichai ^a   Pruksakorn, Dumnoensun ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Bone specific alkaline phosphatase; Chondroitin sulfate; Osteosarcoma; Tumor volume VEGF; WF6

Indexed keywords

ALKALINE PHOSPHATASE; CHONDROITIN SULFATE; HYALURONIC ACID; LACTATE DEHYDROGENASE; TUMOR MARKER; VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BONE TUMOR; CASE CONTROL STUDY; CHILD; FEMALE; HUMAN; MALE; MIDDLE AGED; OSTEOSARCOMA; PATHOLOGY; TUMOR VOLUME;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BONE NEOPLASMS; CASE-CONTROL STUDIES; CHILD; CHONDROITIN SULFATES; FEMALE; HUMANS; HYALURONIC ACID; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; OSTEOSARCOMA; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTORS; YOUNG ADULT;

EID: 84864359009     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bacci G, Longhi A, Versari M, et al (2006). Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer, 106, 1154-61.
2. Berdiaki A, Datsis GA, Nikitovic D, et al (2010). Parathyroid hormone (PTH) peptides through the regulation of hyaluronan metabolism affect osteosarcoma cell migration. IUBMB Life, 62, 377-86.
3. Ek ET, Ojaimi J, Kitagawa Y, et al (2006). Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep, 16, 17-23.
4. Fuster MM, Esko JD (2005). The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer, 5, 526-42.
5. Garcia R, Hernandez JM, Caballero MD, et al (1993). Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. Br J Cancer, 68, 1227-31.
6. Harting MT, Blakely ML, Jaffe N, et al (2006). Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg, 41, 194-9.
7. Hauben EI, Weeden S, Pringle J, et al (2002). Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer, 38, 1218-25.
8. Holzer G, Obermair A, Koschat M, et al (2001). Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediatr Oncol, 36, 601-4.
9. Kaya M, Wada T, Kawaguchi S, et al (2002). Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer, 86, 864-9.
10. Kaya M, Wada T, Nagoya S, et al (2009). The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J Bone Joint Surg Br, 91, 784-8.
11. Leung KS, Fung KP, Sher AH, et al (1993). Plasma bone-specific alkaline phosphatase as an indicator of osteoblastic activity. J Bone Joint Surg Br, 75, 288-92.
12. Lin F, Zheng S-E, Shen Z, et al (2011). Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol, 62, 3436-46.
13. Liu D, Shriver Z, Venkataraman G, et al (2002). Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA, 99, 568-73.
14. Misra S, Ghatak S, Zoltan-Jones A, et al (2003). Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem, 278, 25285-8.
15. Moon SH, Shin KH, Suh JS, et al (2005). Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma. Yonsei Med J, 46, 119-24.
16. Nguyen DX, Bos PD, Massague J (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer, 9, 274-84.
17. Nikitovic D, Zafiropoulos A, Katonis P, et al (2006). Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life, 58, 47-53.
18. Pothacharoen P, Kalayanamitra K, Deepa SS, et al (2007). Two related but distinct chondroitin sulfate mimetope octasaccharide sequences recognized by monoclonal antibody WF6. J Biol Chem, 282, 35232-46.
19. Pothacharoen P, Siriaunkgul S, Ong-Chai S, et al (2006). Raised Serum Chondroitin Sulfate Epitope Level in Ovarian Epithelial Cancer. Journal of Biochemistry, 140, 517-24.
20. Pothacharoen P, Teekachunhatean S, Louthrenoo W, et al (2006). Raised chondroitin sulfate epitopes and hyaluronan in serum from rheumatoid arthritis and osteoarthritis patients. Osteoarthritis and Cartilage, 14, 299-301.
21. Pruksakorn D, Lirdprapamongkol K, Chokchaichamnankit D, et al (2010). Metabolic alteration of HepG2 in scaffold-based 3-D culture: Proteomic approach. Proteomics, 10, 3896-904.
22. Rasalkar DD, Chu W, Lee V, et al (2011). Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival. Pediatric Radiology, 41, 227-36.
23. Rossi B, Schinzari G, Maccauro G, et al (2010). Neoadjuvant multidrug chemotherapy including High-Dose Methotrexate modifies VEGF expression in Osteosarcoma: an immunohistochemical analysis. BMC Musculoskeletal Disord, 11, 34.
24. Sawyers CL (2008) The cancer biomarker problem. Nature, 452, 548-52.
25. Shin KH, Moon SH, Suh JS, et al (2000). Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res, 376, 200-8.
26. Stein GS, Lian JB, Owen TA (1990) Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J, 4, 3111-23.
27. Tas F, Aykan F, Alici S, et al (2001). Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol, 24, 547-50.
28. Timar J, Lapis K, Dudas J, et al (2002). Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol, 12, 173-86.
29. Tofuku K, Yokouchi M, Murayama T, et al (2006). HAS3-related hyaluronan enhances biological activities necessary for metastasis of osteosarcoma cells. Int J Oncol, 29, 175-83.